How Much Does an AI-Written Clinical Evaluation Report Actually Cost?

The EU and US markets remain the most attractive expansion targets for medical device manufacturers looking to grow beyond their home market: higher price points, larger volumes, and the credibility that comes with CE marking or FDA registration. The topic comes up constantly — at trade shows, in distributor conversations, in manufacturer forums: who has already gotten in, what it cost, what documentation was actually required.

In 2026, the natural first move is no longer to ask a consultant or a CRO — it’s to ask an AI model. How much does CE marking cost? What’s the document list for a technical file? Can this be done in-house, without outside help? The answers sound confident and well-structured: a list of documents, the steps of the procedure, even rough timelines. It’s easy to conclude the task is manageable internally — and that’s usually where the next decision gets made.

A regulatory or quality team member, asked to draft a Clinical Evaluation Report (CER) under MEDDEV 2.7/1 Rev 4 for the first time, opens an AI chat and asks it to write one. At first glance, the output looks solid: correct structure, sections that formally match MEDDEV, an appraisal table, references to standards. Skim through it, and everything looks done.

Who Actually Reads It

That file doesn’t land on a generalist’s desk for a once-over. For device classes requiring conformity assessment, the documentation is reviewed by specialists engaged by the Notified Body — the body specifically designated to carry out conformity assessment under the MDR. For these reviewers, checking a CER is daily work. They aren’t looking at the structure; they’re looking at the actual numbers, citations, and the logic connecting them.

Where Form and Fact Diverge

This is where a gap opens up between the form of the document and the facts that form is supposed to contain:

• The stated literature search methodology (databases, search strings, dates) is often not reproducible: if a reviewer runs the same query, they won’t get the same results — because the search was actually run through a general web search, not directly against PubMed, Embase, or Cochrane.
• Classifying a study as pivotal or supportive under MEDDEV Appendix A9 requires reading the full text — study design, sample size, conflicts of interest. None of that is visible in a search snippet, and an AI model often fills the gap with whatever “sounds like” the right answer rather than something it has actually verified.
• Claim-to-evidence traceability is a fact, not a pattern. It’s not a boilerplate phrase — it’s a specific, checkable link to a specific study. Without hard data behind it, there’s a real risk that link is simply a plausible-sounding fabrication.

This Is Already a Documented Risk

In April 2026, the FDA issued a warning letter to a pharmaceutical manufacturer that included — for the first time — a standalone section titled “Inappropriate Use of Artificial Intelligence in Pharmaceutical Manufacturing.” The company had used AI agents to generate product specifications, SOPs, and batch records that entered the quality system without human review. When inspectors flagged a missing process validation, the company’s defense was that the AI agent never flagged the requirement. The FDA’s response was unambiguous: using AI to draft documents doesn’t remove a manufacturer’s obligation to verify they’re accurate and compliant before they enter the quality system.

A parallel case outside pharma: a YC-backed compliance automation startup that raised $32M was found to have delivered audit reports to over 400 clients, where 493 of 494 drafts shared near-identical templated language — differing only in client name and signature.

The Takeaway

This isn’t an argument against using AI as a tool. It’s genuinely good at the part of the work that usually has no budget attached: first-pass literature screening, structuring the file, producing a working draft. But there’s one step it can’t replace — someone has to physically open the source document and verify it actually says what the report claims it says. Skip that step before the file reaches the Notified Body’s experts, and the savings almost always turn into lost time and a repeat assessment — the same budget, just spent later, with interest.